CEO: Katherine Bowdish

Advent Contact: Alan Walts

PIC Therapeutics is a biotechnology company focused on fundamentally changing how cancer is treated by developing a new generation of therapeutics based on the modulation of RNA translation.

PIC Therapeutics’ precision-based therapeutics target the “master switch” of cancer signalling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. PIC Therapeutics' selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.

PIC Therapeutics Raises $5 Million to Advance Development of Small Molecules That Selectively Modulate eIF4E

PIC Therapeutics Appoints Dr. Katherine Bowdish as Chief Executive Officer